Literature DB >> 15646407

Tuberculosis in dialysis patients, single centre experience from an endemic area.

R Erkoc1, E Dogan, H Sayarlioglu, O Etlik, C Topal, F Calka, K Uzun.   

Abstract

Because of immunity defect, patients with end-stage renal disease are at increased risk of developing infections, tuberculosis (TB) in particular. The incidence of TB is higher in dialysis patients than in general population. We retrospectively reviewed the charts of dialysis patients with TB in our facility. A total of 287 dialysis patients (153 male, 134 female, 223 haemodialysis (HD), 64 continuous ambulatory peritoneal dialysis (CAPD) patients, mean age 46 +/- 15) were reviewed from October 1997 to January 2002. TB developed in 30 patients (17 male, 13 female, 24 HD and six CAPD). Thirteen patients with TB presented with fever of unknown origin (FUO) and four of them subsequently developed military lesions on chest X-ray. Nine patients had pulmonary TB (four with pleural effusions), five patients had TB lymphadenits, two patients had TB peritonitis and one patient had vertebral TB. TB was presented mostly as FUO among dialysis patients in a region under poor socio-economic conditions. In such areas with endemic TB, dialysis patients who present with FUO should be carefully evaluated for the presence of TB, and test therapy for TB should be performed in otherwise unexplained FUO.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15646407     DOI: 10.1111/j.1742-1241.2004.00212.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  2 in total

1.  Infections in hemodialysis: a concise review - Part 1: bacteremia and respiratory infections.

Authors:  T Eleftheriadis; V Liakopoulos; K Leivaditis; G Antoniadi; I Stefanidis
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

2.  Geographic prediction of tuberculosis clusters in Fukuoka, Japan, using the space-time scan statistic.

Authors:  Daisuke Onozuka; Akihito Hagihara
Journal:  BMC Infect Dis       Date:  2007-04-11       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.